Gene therapy of cancer : methods and protocols /
Saved in:
Edition: | 2nd ed. |
---|---|
Imprint: | New York, NY : Humana Press, ©2009. |
Description: | 1 online resource (xiv, 731 pages) : illustrations (some color) |
Language: | English |
Series: | Springer protocols Methods in molecular biology, 1940-6029 ; 542 Methods in molecular biology (Clifton, N.J.) ; v. 542. Springer protocols. |
Subject: | |
Format: | E-Resource Book |
URL for this record: | http://pi.lib.uchicago.edu/1001/cat/bib/11199472 |
Table of Contents:
- Preface
- Contributors
- Section I. Experimental Approaches in Cancer Therapy
- Subsection A. Introduction
- 1. The Development of Gene Therapy: From Monogenic Recessive Disorders to Complex Diseases Such as Cancer
- Subsection B. Vectorology For Cancer Gene Therapy
- 2. Designing Adenoviral Vectors for Tumor-Specific Targeting
- 3. Analysis of HSV Oncolytic Virotherapy in Organotypic Cultures
- 4. Use of Minicircle Plasmids for Gene Therapy
- 5. Transposable Elements as Plasmid-Based Vectors for Long-Term Gene Transfer into Tumors
- 6. Designing Plasmid Vectors
- 7. Development of Bacterial Vectors for Tumor-Targeted Gene Therapy
- Subsection C. Nonviral Transfer Technologies in Cancer Gene Therapy
- 8. Electroporative Gene Transfer
- 9. Gene Gun Delivery Systems for Cancer Vaccine Approaches
- 10. Ultrasound-Mediated Gene Transfection
- 11. Nonviral Jet-Injection Technology for Intratumoral In Vivo Gene Transfer of Naked DNA
- Subsection D. Experimental Studies In Cancer Gene Therapy
- 12. Methods for Constructing and Evaluating Antitumor DNA Vaccines
- 13. Immunity of Lentiviral Vector-Modified Dendritic Cells
- 14. Saporin Suicide Gene Therapy
- 15. Using In Vivo Biopanning for the Development of Radiation-Guided Drug Delivery Systems
- 16. Chemosensitization of Tumor Cells: Inactivation of Nuclear Factor-Kappa B Associated with Chemosensitivity in Mealanoma Cels After Combination Treatment with E2F-1 and Doxorubicin
- 17. Induction of Tumor Cell Apoptosis by TRAIL Gene Therapy
- 18. Silencing Epidermal Growth Factor Receptor by RNA Interference in Glioma
- 19. Delivery of Phosphorodiamidate Morpholino Antisense Oligomers in Cancer Cells
- 20. Use of RNA Aptamers for the Modulation of Cancer Cell Signaling
- 21. G-Rich Oligonucleotides for Cancer Treatment
- Section II. Clinical Approaches in Cancer Gene Therapy
- Subsection A. Requirements for Clinical Gene Therapy Trials
- 22. Regulatory Aspects for Translating Gene Therapy Research into the Clinic
- 23. Ethics of Cancer Gene Transfer Clinical Research
- 24. Virus Production for Clinical Gene Therapy
- 25. Production of Plasmid DNA as Pharmaceutical
- Subsection B. Clinical Protocols in Cancer Gene Therapy
- 26. Gene Immunotherapy for Non-Small Cell Lung Cancer
- 27. Gene Therapy for Antitumor Vaccination
- 28. HSV-tk/IL-2 Gene Therapy for Glioblastoma Multiforme
- 29. Construction and Characterization of an Oncolytic HSV Vector Containing a Fusogenic Glycoprotein and Prodrug Activation for Enhanced Local Tumor Control
- 30. Newcastle Disease Virus: A Promising Vector for Viral Therapy, Immune Therapy, and Gene Therapy of Cancer
- 31. Oncolytic Viral Therapy Using Reovirus
- 32. Design and Testing of Novel Oncolytic Vaccinia Strains
- 33. Tumor-Targeted Salmonella typhimurium Overexpressing Cytosine Deaminase: A Novel, Tumor-Selective Therapy
- 34. Chemoprotection by Transfer of Resistance Genes
- 35. Phase I Clinical Trial of Locoregional Administration of the Oncolytic Adenovirus ONYX-015 in Combination with Mitomycin-C, Doxorubicin, and Cisplatin Chemotherapy in Patients with Advanced Sarcomas
- Index